NASDAQ$PRVA
Privia Health Group, Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Reported financial results for the fourth quarter and full year ended December 31, 2021.
Privia Health's Q4 2021 financial performance showed strong growth, with practice collections, care margin, and adjusted EBITDA exceeding the high end of the company's full-year financial guidance. The company also saw growth in implemented providers and attributed lives, and is expanding into new markets.
- Total revenue for the fourth quarter of 2021 was $275.3 million, a 28.8% increase compared to the prior year fourth quarter.
- Operating loss for the fourth quarter of 2021 was $19.3 million, compared to operating income of $4.2 million for the prior year fourth quarter.
- Practice Collections for the fourth quarter of 2021 were $513.2 million, a 45.8% increase compared to the same period in 2020.
- Implemented Providers for the fourth quarter of 2021 were 3,317, a 30.1% increase compared to the end of the fourth quarter of 2020.
Headline financials
Revenue & EPS history
Privia Health · Revenue · Quarterly
$275M
Revenue by segment
Privia Health · $417M total across 6 segments · Q3 2023
- FFS-patient care$246M—58.8%
- Capitated revenue$88.5M—21.2%
- Shared savings$33.5M—8.0%
- FFS-administrative services$29.8M—7.2%
- Care management fees (PMPM)$17.8M—4.3%
- Other revenue$2.03M—0.5%
Forward guidance
Privia Health provided full-year 2022 guidance, reflecting management's expectations for growth from existing markets, recent market entries, new capitated agreements, and investments to support future growth.
Tailwinds
- Implemented Providers between 3,625 and 3,725, representing a 9.3% to 12.3% increase from FY 2021.
- Attributed Lives between 860,000 and 890,000, representing a 9.4% to 13.2% increase from FY 2021.
- Practice Collections between $2.05 billion and $2.2 billion, representing a 26.1% to 35.3% increase from FY 2021.
- GAAP Revenue between $1.225 billion and $1.3 billion, representing a 26.8% to 34.5% increase from FY 2021.
- Adjusted EBITDA between $52 million and $56 million, representing a 25.6% to 35.3% increase from FY 2021.
Headwinds
- 2022 guidance includes only previously announced new market entries.
- Adjusted EBITDA guidance includes approximately $4-6 million in spending/costs to invest in and support recent new market entry and value-based care initiatives.
- Capital expenditures expected to be less than $1 million in full-year 2022.
- Management has not reconciled forward-looking non-GAAP measures to their most directly comparable GAAP measures of operating income and net income.
- The ultimate outcome of certain GAAP components of such reconciliations is uncertain due to market-related assumptions and certain legal, advisory, or tax costs.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2021
+3.5%
Avg return
Earnings day
+4.1%
Avg return
5 days after
+1.3%
Avg return
30 days after
64%
16 / 25 earnings
Positive
+28.3%
Q1 2022
Best reaction
-8.8%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.1% | -4.1% | -9.9% | |
| Q4 2025 | +9.9% | +4.9% | -11.6% | |
| Q3 2025 | -4.3% | -2.8% | -4.7% | |
| Q1 2025 | +7.3% | +4.2% | -0.6% | |
| Q4 2024 | +5.8% | +6.1% | -6.1% | |
| Q3 2024 | +0.7% | +6.7% | +0.1% | |
| Q2 2024 | +4.4% | +9.7% | +2.1% | |
| Q1 2024 | -4.7% | -4.3% | -9.1% | |
| Q4 2023 | +9.4% | +11.6% | -2.0% | |
| Q3 2023 | +9.7% | +9.0% | +6.0% | |
| Q2 2023 | +1.6% | -1.2% | -2.3% | |
| Q1 2023 | +7.3% | +7.2% | -8.3% | |
| Q4 2022 | +4.6% | +6.3% | +1.7% | |
| Q3 2022 | +5.3% | +6.2% | -9.7% | |
| Q2 2022 | +0.6% | -4.6% | +13.3% | |
| Q1 2022 | +28.3% | +25.1% | +41.0% | |
| Q4 2019 | -2.0% | +6.4% | -3.5% | |
| Q4 2021 | +3.3% | +7.5% | +10.4% | |
| Q3 2020 | +12.3% | +18.3% | -14.5% | |
| Q3 2021 | +12.3% | +18.3% | -14.5% | |
| Q2 2020 | -8.8% | -14.8% | -26.5% | |
| Q2 2021 | -8.8% | -14.8% | -26.5% | |
| Q4 2020 | -2.2% | +0.7% | +34.8% | |
| Q1 2020 | -2.2% | +0.7% | +34.8% | |
| Q1 2021 | -1.1% | +0.9% | +39.1% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro